Clinical Research Directory

Inclusion Criteria: * Participants must be adults (≥18 years) who have signed an informed consent form. * They should have an ECOG performance status of 0-1. Diagnosed with stage IIIB-IV NSCLC and have progressed after PD-1 inhibitor treatment. * Expected to live at least 3 months and have at least one measurable lesion per RECIST v1.1. * Laboratory test results must meet specific criteria for blood counts, liver and kidney function, and coagulation parameters. * Patients with stable, treated brain metastases are eligible. * Women of childbearing potential and men with partners of childbearing potential must agree to use contraception. Exclusion Criteria: * Prior therapy with anti-PD-L1, anti-PD-L2, other immune checkpoint inhibitors, or specific cancer treatments. * Certain cancer types, known mutations, or recent use of systemic corticosteroids or immunosuppressive medications. * Active brain or leptomeningeal metastases without stability post-treatment, recent severe infections, or major surgery. * Other conditions that might interfere with the study, such as uncontrollable third-space fluid accumulations, active autoimmune diseases or infections, significant bleeding or thromboembolic events, serious heart conditions, severe allergies to study drugs, other active malignancies, HIV/AIDS, hepatitis B or C infection, or participation in another interventional clinical study within a specified period.